Literature DB >> 20306109

The costs of breast cancer prior to and following diagnosis.

Steven Broekx1, Elly Den Hond, Rudi Torfs, Anne Remacle, Raf Mertens, Thomas D'Hooghe, Patrick Neven, Marie-Rose Christiaens, Steven Simoens.   

Abstract

This retrospective incidence-based cost-of-illness analysis aims to quantify the costs associated with female breast cancer in Flanders for the year prior to diagnosis and for each of the 5 years following diagnosis. A bottom-up analysis from the societal perspective included direct health care costs and indirect costs of productivity loss due to morbidity and premature mortality. A case-control study design compared total costs of breast cancer patients with costs of an equivalent standardised population with a view to calculating the additional costs that can be attributed to breast cancer. Total average costs of breast cancer amounted to 107,456 <euro> per patient over 6 years. Total costs consisted of productivity loss costs (89% of costs) and health care costs (11% of costs). Health care costs did not vary with age at diagnosis. Health care costs of breast cancer patients converged with those of the general population at 5 years following diagnosis. Patients with advanced breast cancer stadia had higher health care costs. Cost estimates provided by this analysis can be used to determine priorities for, and inform, future research on breast cancer. In particular, attention needs to be focussed on decreasing productivity loss from breast cancer.

Entities:  

Mesh:

Year:  2010        PMID: 20306109     DOI: 10.1007/s10198-010-0237-3

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN: 1618-7598


  13 in total

1.  Assessing the economic burden of breast cancer in a US managed care population.

Authors:  John J Barron; Ralph Quimbo; Prashant T Nikam; Mayur M Amonkar
Journal:  Breast Cancer Res Treat       Date:  2007-08-03       Impact factor: 4.872

2.  Cost of breast cancer in Sweden in 2002.

Authors:  Mathias Lidgren; Nils Wilking; Bengt Jönsson
Journal:  Eur J Health Econ       Date:  2007-03

3.  Cost-of-illness methodology: a guide to current practices and procedures.

Authors:  T A Hodgson; M R Meiners
Journal:  Milbank Mem Fund Q Health Soc       Date:  1982

4.  The excess cost of acute exacerbations of chronic bronchitis in patients aged 45 and older in England and Wales.

Authors:  A McGuire; D E Irwin; P Fenn; A Gray; P Anderson; A Lovering; A MacGowan
Journal:  Value Health       Date:  2001 Sep-Oct       Impact factor: 5.725

Review 5.  Advances in breast cancer: pathways to personalized medicine.

Authors:  Olufunmilayo I Olopade; Tatyana A Grushko; Rita Nanda; Dezheng Huo
Journal:  Clin Cancer Res       Date:  2008-12-15       Impact factor: 12.531

6.  Health care costs for treatment of disseminated breast cancer.

Authors:  L Dahlberg; J Lundkvist; H Lindman
Journal:  Eur J Cancer       Date:  2009-04-22       Impact factor: 9.162

7.  Cost of illness associated with metastatic breast cancer.

Authors:  S Rao; J Kubisiak; D Gilden
Journal:  Breast Cancer Res Treat       Date:  2004-01       Impact factor: 4.872

8.  The decrease in breast-cancer incidence in 2003 in the United States.

Authors:  Peter M Ravdin; Kathleen A Cronin; Nadia Howlader; Christine D Berg; Rowan T Chlebowski; Eric J Feuer; Brenda K Edwards; Donald A Berry
Journal:  N Engl J Med       Date:  2007-04-19       Impact factor: 91.245

9.  Exploring the economic impact of breast cancers during the 18 months following diagnosis.

Authors:  Louisa Gordon; Paul Scuffham; Sandi Hayes; Beth Newman
Journal:  Psychooncology       Date:  2007-12       Impact factor: 3.894

10.  Cost of managing women presenting with stage IV breast cancer in the United Kingdom.

Authors:  E Remák; L Brazil
Journal:  Br J Cancer       Date:  2004-07-05       Impact factor: 7.640

View more
  23 in total

1.  Caring for relatives with lung cancer in Europe: an evaluation of caregivers' experience.

Authors:  Jacek Jassem; John R Penrod; Amir Goren; Isabelle Gilloteau
Journal:  Qual Life Res       Date:  2015-06-12       Impact factor: 4.147

2.  Comparative cost-effectiveness of bazedoxifene and raloxifene in the treatment of postmenopausal osteoporosis in Europe, using the FRAX algorithm.

Authors:  K Kim; A Svedbom; X Luo; S Sutradhar; J A Kanis
Journal:  Osteoporos Int       Date:  2013-10-10       Impact factor: 4.507

3.  HR+/HER2- Metastatic Breast Cancer: Epidemiology, Prescription Patterns, Healthcare Resource Utilisation and Costs from a Large Italian Real-World Database.

Authors:  Carlo Piccinni; Letizia Dondi; Giulia Ronconi; Silvia Calabria; Antonella Pedrini; Immacolata Esposito; Nello Martini; Maurizio Marangolo
Journal:  Clin Drug Investig       Date:  2019-10       Impact factor: 2.859

4.  Health system costs for stage-specific breast cancer: a population-based approach.

Authors:  N Mittmann; J M Porter; J Rangrej; S J Seung; N Liu; R Saskin; M C Cheung; N B Leighl; J S Hoch; M Trudeau; W K Evans; K N Dainty; C DeAngelis; C C Earle
Journal:  Curr Oncol       Date:  2014-12       Impact factor: 3.677

Review 5.  Role of trastuzumab in the management of HER2-positive metastatic breast cancer.

Authors:  Andrea Milani; Filippo Montemurro; Luisa Gioeni; Massimo Aglietta; Giorgio Valabrega
Journal:  Breast Cancer (Dove Med Press)       Date:  2010-11-24

6.  Comparison of Treatment Costs for Breast Cancer, by Tumor Stage and Type of Service.

Authors:  Helen Blumen; Kathryn Fitch; Vincent Polkus
Journal:  Am Health Drug Benefits       Date:  2016-02

7.  Healthcare costs associated with breast cancer in Germany: a claims data analysis.

Authors:  Kristine Kreis; Marika Plöthner; Torben Schmidt; Richard Seufert; Katharina Schreeb; Veronika Jahndel; Sylke Maas; Alexander Kuhlmann; Jan Zeidler; Anja Schramm
Journal:  Eur J Health Econ       Date:  2020-01-02

8.  Predicting cancer mortality: Developing a new cancer care variable using mixed methods and the quasi-statistical approach.

Authors:  Susan L Zickmund; Suzanne Yang; Edward P Mulvey; James E Bost; Laura A Shinkunas; Douglas R LaBrecque
Journal:  Health Serv Res       Date:  2013-10-21       Impact factor: 3.402

Review 9.  The global impact of non-communicable diseases on healthcare spending and national income: a systematic review.

Authors:  Taulant Muka; David Imo; Loes Jaspers; Veronica Colpani; Layal Chaker; Sven J van der Lee; Shanthi Mendis; Rajiv Chowdhury; Wichor M Bramer; Abby Falla; Raha Pazoki; Oscar H Franco
Journal:  Eur J Epidemiol       Date:  2015-01-18       Impact factor: 8.082

10.  Determining Breast Cancer Treatment Costs Using the Top Down Cost Approach.

Authors:  Rukiye Numanoğlu Tekin; Meltem Saygılı
Journal:  Eur J Breast Health       Date:  2019-10-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.